Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
Identifieur interne : 001140 ( Pmc/Checkpoint ); précédent : 001139; suivant : 001141Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
Auteurs : V. Pernin ; L. Belin ; P. Cottu ; P. Bontemps ; C. Lemanski ; B. De La Lande ; P. Baumann ; F. Missohou ; C. Levy ; K. Peignaux ; A. Reynaud-Bougnoux ; F. Denis ; A. Gobillion ; M. Bollet ; N A Vago ; R. Dendale ; F. Campana ; A. Fourquet ; Y M KirovaSource :
- The British Journal of Radiology [ 0007-1285 ] ; 2015.
Abstract
To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).
Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.
From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1–2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).
The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.
The largest series of this association.
Url:
DOI: 10.1259/bjr.20140800
PubMed: 25645108
PubMed Central: 4651262
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:4651262Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer</title>
<author><name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<affiliation><nlm:aff id="aff5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<affiliation><nlm:aff id="aff6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<affiliation><nlm:aff id="aff7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<affiliation><nlm:aff id="aff8"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<affiliation><nlm:aff id="aff9"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<affiliation><nlm:aff id="aff10"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<affiliation><nlm:aff id="aff11"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<affiliation><nlm:aff id="aff12"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
<affiliation><nlm:aff id="aff13"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25645108</idno>
<idno type="pmc">4651262</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651262</idno>
<idno type="RBID">PMC:4651262</idno>
<idno type="doi">10.1259/bjr.20140800</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">000256</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000256</idno>
<idno type="wicri:Area/Pmc/Curation">000256</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000256</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001140</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001140</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer</title>
<author><name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<affiliation><nlm:aff id="aff5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<affiliation><nlm:aff id="aff6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<affiliation><nlm:aff id="aff7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<affiliation><nlm:aff id="aff8"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<affiliation><nlm:aff id="aff9"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<affiliation><nlm:aff id="aff10"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<affiliation><nlm:aff id="aff11"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<affiliation><nlm:aff id="aff12"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
<affiliation><nlm:aff id="aff13"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">The British Journal of Radiology</title>
<idno type="ISSN">0007-1285</idno>
<idno type="eISSN">1748-880X</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Objective:</title>
<p>To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).</p>
</sec>
<sec><title>Methods:</title>
<p>Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.</p>
</sec>
<sec><title>Results:</title>
<p>From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1–2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).</p>
</sec>
<sec><title>Conclusion:</title>
<p>The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.</p>
</sec>
<sec><title>Advances in knowledge:</title>
<p>The largest series of this association.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Radiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br J Radiol</journal-id>
<journal-id journal-id-type="publisher-id">bjr</journal-id>
<journal-title-group><journal-title>The British Journal of Radiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1285</issn>
<issn pub-type="epub">1748-880X</issn>
<publisher><publisher-name>The British Institute of Radiology.</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">25645108</article-id>
<article-id pub-id-type="pmc">4651262</article-id>
<article-id pub-id-type="publisher-manuscript">14800</article-id>
<article-id pub-id-type="doi">10.1259/bjr.20140800</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Full Paper</subject>
</subj-group>
<subj-group subj-group-type="collection"><subject>Breast</subject>
<subject>Interventional and Vascular</subject>
<subject>Neuroradiology</subject>
</subj-group>
</article-categories>
<title-group><article-title>Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer</article-title>
<alt-title alt-title-type="left-running-head">V Pernin <italic>et al</italic>
</alt-title>
<alt-title alt-title-type="right-running-head">Adjuvant radiotherapy combined with concurrent bevacizumab</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Pernin</surname>
<given-names>V</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Belin</surname>
<given-names>L</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2"><sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Cottu</surname>
<given-names>P</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3"><sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bontemps</surname>
<given-names>P</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4"><sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lemanski</surname>
<given-names>C</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5"><sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>De La Lande</surname>
<given-names>B</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff6"><sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Baumann</surname>
<given-names>P</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff7"><sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Missohou</surname>
<given-names>F</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff8"><sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Levy</surname>
<given-names>C</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff9"><sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Peignaux</surname>
<given-names>K</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff10"><sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Reynaud-Bougnoux</surname>
<given-names>A</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff11"><sup>11</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Denis</surname>
<given-names>F</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff12"><sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Gobillion</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bollet</surname>
<given-names>M</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Vago</surname>
<given-names>N A</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff13"><sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Dendale</surname>
<given-names>R</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Campana</surname>
<given-names>F</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Fourquet</surname>
<given-names>A</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Kirova</surname>
<given-names>Y M</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1"><sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><label><sup>1</sup>
</label>
<addr-line>Radiotherapy Department, Institut Curie, Paris, France</addr-line>
</aff>
<aff id="aff2"><label><sup>2</sup>
</label>
<addr-line>Biostatistics Department, Institut Curie, Paris, France</addr-line>
</aff>
<aff id="aff3"><label><sup>3</sup>
</label>
<addr-line>Oncology Department, Institut Curie, Paris, France</addr-line>
</aff>
<aff id="aff4"><label><sup>4</sup>
</label>
<addr-line>Radiotherapy Department, CHU Jean Minjoz, Besançon, France</addr-line>
</aff>
<aff id="aff5"><label><sup>5</sup>
</label>
<addr-line>Radiotherapy Department, Institut régional du Cancer de Montpellier, Montpellier, France</addr-line>
</aff>
<aff id="aff6"><label><sup>6</sup>
</label>
<addr-line>Radiotherapy Department, Institut Curie, Rene Huguenin Hospital, Saint Cloud, France</addr-line>
</aff>
<aff id="aff7"><label><sup>7</sup>
</label>
<addr-line>Radiotherapy Department, Centre d'Oncologie de Gentilly, Nancy, France</addr-line>
</aff>
<aff id="aff8"><label><sup>8</sup>
</label>
<addr-line>Radiotherapy Department, Centre Henri Becquerel, Rouen, France</addr-line>
</aff>
<aff id="aff9"><label><sup>9</sup>
</label>
<addr-line>Radiotherapy Department, Centre François Baclesse, Caen, France</addr-line>
</aff>
<aff id="aff10"><label><sup>10</sup>
</label>
<addr-line>Radiotherapy Department, Centre Georges-François Leclerc, Dijon, France</addr-line>
</aff>
<aff id="aff11"><label><sup>11</sup>
</label>
<addr-line>Oncology Department, CHU Tours, Tours, France</addr-line>
</aff>
<aff id="aff12"><label><sup>12</sup>
</label>
<addr-line>Radiotherapy Department, Centre Jean Bernard, Le Mans, France</addr-line>
</aff>
<aff id="aff13"><label><sup>13</sup>
</label>
<addr-line>Roche SAS, Boulogne-Billancourt, France</addr-line>
</aff>
</contrib-group>
<author-notes><corresp id="cor1">Address correspondence to: Dr Youlia M. Kirova. E-mail: <email xlink:href="youlia.kirova@curie.fr">youlia.kirova@curie.fr</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>4</month>
<year>2015</year>
<string-date>April 2015</string-date>
</pub-date>
<pub-date pub-type="epub"><day>19</day>
<month>2</month>
<year>2015</year>
</pub-date>
<volume>88</volume>
<issue>1048</issue>
<elocation-id>20140800</elocation-id>
<history><date date-type="received"><day>27</day>
<month>11</month>
<year>2014</year>
<string-date>Received on November 27, 2014</string-date>
</date>
<date date-type="rev-recd"><day>27</day>
<month>1</month>
<year>2015</year>
<string-date>Revised on January 27, 2015</string-date>
</date>
<date date-type="accepted"><day>2</day>
<month>2</month>
<year>2015</year>
<string-date>Accepted on February 2, 2015</string-date>
</date>
</history>
<permissions><copyright-statement>© 2015 The Authors. Published by the British Institute of Radiology</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>The Authors</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="bjr.20140800.pdf"></self-uri>
<abstract><sec><title>Objective:</title>
<p>To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).</p>
</sec>
<sec><title>Methods:</title>
<p>Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.</p>
</sec>
<sec><title>Results:</title>
<p>From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1–2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).</p>
</sec>
<sec><title>Conclusion:</title>
<p>The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.</p>
</sec>
<sec><title>Advances in knowledge:</title>
<p>The largest series of this association.</p>
</sec>
</abstract>
<counts><fig-count count="1"></fig-count>
<table-count count="5"></table-count>
<ref-count count="5"></ref-count>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001140 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 001140 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Pmc |étape= Checkpoint |type= RBID |clé= PMC:4651262 |texte= Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:25645108" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |